Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-efgartigimod Study: Prednisolone Dose Reduction in Generalized Myasthenia Gravis
jRCTs031240366Active, not recruiting
- Sponsor
- argenx
- Start
- Nov 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoint: Primary: Change in prednisolone dose from baseline. Started Nov 2024; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCTs031240366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240366.